Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.47 |
| ▸ | BHMT | Q93088 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20127148 | 0.81 | ALDH1A1 (0.39) | KMT2ATSHRALDH1A1 | |
| SCHEMBL16411033 | 0.80 | PLA2G4B (0.54) | LMNAKMT2AHSD17B10TDP1PLA2G4B | |
| SCHEMBL14473679 | 0.80 | LMNA (0.45) | LMNAKMT2AHSD17B10TDP1PLA2G4B | |
| SCHEMBL12590394 | 0.80 | PLA2G4B (0.42) | LMNAKMT2AHSD17B10TDP1PLA2G4B | |
| SCHEMBL10879931 | 0.80 | ALDH1A1 (0.52) | LMNAKMT2AHSD17B10TDP1TSHR | |
| SCHEMBL17909259 | 0.78 | TSHR (0.46) | LMNAKMT2AHSD17B10TDP1TSHR | |
| SCHEMBL10599228 | 0.78 | ALDH1A1 (0.55) | LMNAKMT2AHSD17B10TDP1TSHR | |
| SCHEMBL10596601 | 0.78 | ALDH1A1 (0.55) | LMNAKMT2AHSD17B10TDP1TSHR | |
| SCHEMBL17909058 | 0.78 | TSHR (0.46) | LMNAKMT2AHSD17B10TDP1TSHR | |
| SCHEMBL17908953 | 0.78 | TSHR (0.46) | LMNAKMT2AHSD17B10TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030207-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-02-01 | — | — | US | disclosed |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-02-23 | — | — | US | disclosed |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150025126-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-01-22 | — | — | US | disclosed |
| US-20130197210-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8277846-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120172525-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8092833-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-07-28 | — | — | US | disclosed |
| US-7968123-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110144190-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-06-16 | — | — | US | disclosed |
| US-7807198-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080279954-A1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7375096-B1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070025952-A1 | Linear cyclodextrin copolymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-02-01 | — | — | US | disclosed |
| US-7166302-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025126-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | PICALM, IMMT, PAICS | LMNA 1531/4885KMT2A 4456/4885HSD17B10 2297/4885 |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | LMNA 1557/4885KMT2A 4801/4885HSD17B10 2411/4885 |
| US-20180030207-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | DDOST, SI, PDIA6 | LMNA 3425/4885KMT2A 4873/4885HSD17B10 195/4885 |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | LMNA 1557/4885KMT2A 4801/4885HSD17B10 2411/4885 |
| US-20070025952-A1 | Linear cyclodextrin copolymers | DDOST, SI, PDIA6 | LMNA 3425/4885KMT2A 4873/4885HSD17B10 195/4885 |
| US-20080279954-A1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | PICALM, IMMT, PAICS | LMNA 1531/4885KMT2A 4456/4885HSD17B10 2297/4885 |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | LMNA 1441/4885KMT2A 4806/4885HSD17B10 2149/4885 |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | INTS6, EXOSC5, PCBP1 | LMNA 1557/4885KMT2A 4801/4885HSD17B10 2411/4885 |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | LMNA 1441/4885KMT2A 4806/4885HSD17B10 2149/4885 |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | LMNA 1557/4885KMT2A 4801/4885HSD17B10 2411/4885 |
| US-20110144190-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | PICALM, IMMT, PAICS | LMNA 1531/4885KMT2A 4456/4885HSD17B10 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.